SLC7A5 and biliary tract neoplasm: An example of the therapeutic use of targeting AATs is exemplified by JPH203 (nanvuranlat), an inhibitor of the large amino acid transporter LAT1 (SLC7A5), which is currently in clinical trials for the treatment of biliary tract cancer [4].